Acumen Pharmaceuticals Reports Third-Quarter 2026 Financial Results
The company expects to report topline results from its Phase 2 ALTITUDE-AD study of sabirnetug (ACU193).
The company expects to report topline results from its Phase 2 ALTITUDE-AD study of sabirnetug (ACU193).